跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
EMGALITY - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
EMGALITY
Authorized
STANDARD
EMGALITY
eli lilly canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
0f84d41969bbfad2
Company
eli lilly canada inc
Type
Standard
Approval Details
Approval Id
0f84d41969bbfad2
Drug Approval Canada Name
EMGALITY
Product Name
EMGALITY
Status
Marketed
Status Date
2019-10-02
Original Market Date
2019-10-02
Din
02491087
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
28:32.12
Atc Original
N02CD02 GALCANEZUMAB
Atc Name
n 02 cd 02
Aig Number
0161690001
Company Name
eli lilly canada inc
Company Address
SUITE 900, Exchange Tower, 130 King Street West, Toronto, Ontario, Canada, M5X 1B1
Active Ingredients
GALCANEZUMAB
120 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
0f84d41969bbfad2
Type
Standard
Back to Health Canada Approvals